Advances toward Curing HIV-1 Infection in Tissue Reservoirs
- J Virol. 2020 Jan 17;94(3):e00375-19. doi: 10.1128/JVI.00375-19.
- 1. Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
- 2. Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
- 3. Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA [email protected].
- # Contributed equally.
A disease of more than 39.6 million people worldwide, HIV-1 Infection has no curative therapy. To date, one man has achieved a sterile cure, with millions more hoping to avoid the potential pitfalls of lifelong antiretroviral therapy and Other HIV-related disorders, including neurocognitive decline. Recent developments in immunotherapies and gene therapies provide renewed hope in advancing efforts toward a sterilizing or functional cure. On the horizon is research concentrated in multiple separate but potentially complementary domains: vaccine research, viral transcript editing, T-cell effector response targeting including checkpoint inhibitors, and gene editing. Here, we review the concept of targeting the HIV-1 tissue reservoirs, with an emphasis on the central nervous system, and describe relevant new work in functional cure research and strategies for HIV-1 eradication.
-
Cat. No.Product NameDescriptionTargetResearch Area
-